0219 Primmune ECP
BioCentury & Getty Images

Emerging Company Profile

Primmune: tolerable TLR7 agonists for systemic immune responses

Emerging Company Profile: San Diego-based Primmune is developing oral host-directed antivirals that activate TLR7 signaling

Primmune is developing oral TLR7 agonists to treat viral infections and cancer via systemic activation of innate immunity without inflammation.

Feb 19, 2021 | 11:21 PM GMT

Primmune is designing oral TLR7 agonists that induce antiviral responses without systemically inducing pro-inflammatory genes.

Primmune Therapeutics Inc. President, Chairman and

Read the full 753 word article

How to gain access

Continue reading with a
two-week free trial.